AXGN Axogen, Inc. Common Stock

XNAS 37.46 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

AXGN $37.46 —
Key stats
$37.46
52-Week Range
$17.14 – $52.91
YTD
+20.84%
IV Rank (30D)
61.07
Straddle Price
$8.03
P/C Vol Ratio
0.01
Market Cap
$2.2B
Open
$38.14
Day Range
$37.23 – $39.03
Volume
2,461,071
Prev Close
$38.02
Fair Value
MODEL: SHORT

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.96%
Beta vs SPY1.10
Cost of Equity (CAPM)11.00% (VRP-adj)
WACC11.17%
Volatility Risk Premium+82.7pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+16.1%
DCF Horizon12 years explicit + fade
Forward Tilt (NTM/TTM)×1.10 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$0.0B
Return on Equity (TTM)-13.1%
Book / Price13.5%
Gross Margin (TTM)74.6%
FCF Margin (TTM)3.4%
Debt / Equity0.00
Quality Score4/6 — high quality (12y DCF)
SMA 50$43.04 (Market Anchor value)
SMA 20 / Bollinger Mid$37.14
Bollinger Width / SMA2059.1% (drives anchor stability)
Net Debt$-0.1B
Market Cap$2B
Peers used for multiples: ALKS, ARGX, BIIB, EWTX, GH, NBIX, PTCT, RVMD
60-Day Conviction
36%
20-Day Fair Value
≈ by Nov 25, 2026
$37.62
α +0.4% rank 1%
conviction
27%
40-Day Fair Value
≈ by Dec 24, 2026
$37.70
α +0.7% rank 1%
conviction
22%
60-Day Fair Value
≈ by Jan 22, 2027
$37.08
α -1.0% rank 1%
conviction
36%
MethodImplied PriceWeightDetail
DCF $6.50 56%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 44.4× · 3 peers
Peer EV/EBITDA n/a 0% median 22.9× · 4 peers
Peer P/B $20.75 22% median 4.0× · 5 peers
Peer P/S $24.25 22% median 4.4× · 5 peers
Market Anchor (SMA50) $43.04 0% stability 0% (BB-width)
Options Expected (B-L 30d) $36.48 0% 9 strikes · skew +0.14
As of 2026-10-27 · updated
About
Industry (SIC)
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS (3845) · industry map
Exchange
XNAS
Market Cap
$2.2B
Employees
622
List Date
1986-12-17
CIK
0000805928
Next Earnings
2026-10-28 (Pre-Market)
EPS Forecast
($0.03) (2 est.)
Headquarters
Alachua, FL
Homepage
https://www.axogeninc.com

Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kin…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'21'22'23'24'25'26Avg
Jan-0.91%-12.73%-4.15%39.94%11.04%12.42%7.60%
Feb25.07%8.60%-11.19%8.31%11.66%-9.39%5.51%
Mar-10.35%-12.36%15.81%-24.51%-4.10%8.09%-4.57%
Apr-5.74%-11.27%-4.04%-19.37%-8.65%28.65%-3.40%
May4.91%28.93%-8.31%4.12%-33.92%-8.78%-2.18%
Jun9.36%-11.84%5.67%6.16%-1.09%19.29%4.59%
Jul-6.22%14.08%-2.37%13.88%19.43%-4.96%5.64%
Aug-16.29%-3.90%-26.44%61.15%27.39%11.00%8.82%
Sep-8.99%27.08%-20.63%6.62%13.56%-15.96%0.28%
Oct-5.06%-5.70%-24.80%-2.17%24.34%-6.16%*-3.26%
Nov-37.12%-1.97%81.44%-0.36%23.23%--13.04%
Dec-0.64%-9.52%-0.73%13.19%14.72%--3.40%
Total-49.08%-2.38%-29.24%120.15%115.60%28.24%30.55%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $36.89
SMA 50: $42.80
SMA 200: $39.30
Current: $37.46
EMA 12: $37.10
EMA 26: $38.56
MACD: -1.4661 | Signal: 0.5389
BEARISH
ADX (14): 24.51
WEAK TREND
+DI: 19.97
−DI: 22.45

Momentum Oscillators

RSI (14): 43.79
NEUTRAL
Stoch %K: 82.21
Stoch %D: 75.91
Williams %R: -31.98

Volume & Volatility

BB Upper: $40.17
BB Lower: $33.62
NEUTRAL
OBV: 53,183,002
Vol SMA 20: 1,539,230
Vol ROC: 15.03%
ATR: $1.62
True Range: $1.80
HV 20: 41.0%
HV 30: 38.0%
HV 60: 49.2%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-29T00:00:00 – 2026-10-27T00:00:00
AI Analysis

AXGN Stock Analysis Report

AxoGen, Inc. - Nerve Repair Biomaterials

Executive Summary

Overall Assessment: BEARISH | Confidence Level: 7/10

AxoGen presents a conflicted technical picture with severe near-term bearish signals contradicted by moderately bullish news catalysts and an unusually bullish options market. The stock has declined sharply into oversold territory (-22.6% in 4 weeks), triggering a technical buy-the-dip narrative, but the deteriorating technical structure and recent negative valuation comparison suggest downside risk persists.

Investment Thesis: AXGN is caught between tactical oversold conditions and structural weakness. While the BioCircuit Technologies acquisition (announced Sept 2026) provides strategic narrative support and the options market expects significant movement ($10.85 by 35 DTE), the bearish MACD divergence, strong downtrend momentum (-DI: 30.20), and negative recent sentiment (Oct 16 valuation warning) suggest the current price level may attract sellers on any bounce rather than sustained buyers.

Recent News Sentiment Impact: Mixed. The Sept 10 acquisition announcement was positive, but the Oct 16 "GMED vs AXGN" negative valuation comparison and Oct 5 "buy the dip" recommendation indicate professional skepticism about the current valuation after the recent selloff.

Technical Analysis

Trend Direction

| Timeframe | Direction | Strength | Assessment | |-----------|-----------|----------|------------| | Short-term (1-4 weeks) | DOWNTREND | Strong | Price below SMA 20/50, ADX 31.20 confirms strong directional trend, -DI 30.20 dominates +DI 11.73 | | Medium-term (1-3 months) | DOWNTREND | Moderating | Price well below SMA 50 ($44.41), but above SMA 200 ($39.14); mixed signal | | Long-term (3-12 months) | NEUTRAL/CONSOLIDATION | Weak | Price hovering near 200-day MA; suggests potential reversal zone or range-bound trading |

Support & Resistance Levels

| Level | Type | Distance | Significance | |-------|------|----------|---------------| | $31.97 | Support | -7.6% | Bollinger Band lower band; psychological support | | $34.62 | Current Price | — | Testing recent support zone | | $37.01-$39.14 | Support Cluster | +6.9-13.0% | EMA 12 + SMA 200 convergence zone; major bounce target | | $39.30 | Resistance | +13.6% | SMA 20; must clear to confirm reversal | | $44.41 | Resistance | +28.3% | SMA 50; key trend reversal level | | $46.63 | Resistance | +34.8% | Bollinger Band upper band; technical ceiling |

Momentum Signals

RSI (14): 27.31 — OVERSOLD

  • Extreme oversold reading below 30 threshold typically signals capitulation and potential reversal bounce
  • However, oversold RSI can persist in strong downtrends; not a standalone buy signal
  • Suggests momentum exhaustion but requires confirmation from other indicators

MACD: -2.67 (line) vs -0.23 (signal) — BEARISH DIVERGENCE

  • MACD line remains deeply negative and below signal line
  • Histogram at -2.44 shows strengthening bearish momentum despite recent oversold conditions
  • Critical Issue: MACD has NOT crossed above signal line; no bullish crossover confirmation yet
  • This contradicts the oversold RSI and suggests downside momentum could continue despite extreme readings

Bollinger Bands: NEUTRAL SIGNAL

  • Price at $34.62 vs lower band at $31.97 = moderate distance from lower band
  • Band width at 37.30 is elevated, indicating elevated volatility environment
  • Price is NOT pinned to either extreme; lacks clear mean-reversion setup
  • Band compression would precede significant breakout move

Volume Analysis

Critical Red Flag: Volume Rate of Change -63.84%

  • Volume on recent selling has collapsed dramatically below 20-day average (1.47M)
  • This is a MAJOR warning sign: weak selling volume can indicate capitulation, BUT it also suggests lack of institutional accumulation
  • Current volume insufficient to confirm institutional support for bounce

On-Balance Volume: 51.61M

  • OBV has deteriorated steadily in line with price decline
  • No inflection point suggesting buying pressure building at current levels
  • Suggests institutional money has been exiting, not accumulating dips

Volume SMA 20 Context:

  • Current volume well below average indicates retail-driven selling exhaustion
  • Typical bounce pattern requires volume confirmation on upside; currently absent

News & Sentiment Analysis

Recent Headlines Summary

| Date | Headline | Sentiment | Relevance | |------|----------|-----------|-----------| | 2026-10-16 | GMED vs AXGN valuation comparison | NEGATIVE | Direct bearish valuation assessment; most recent signal | | 2026-10-13 | DexCom retention recommendation | Positive | Competitor bullish; neutral for AXGN | | 2026-10-05 | "Buy the dip" (down 22.6% in 4 weeks) | Positive | Technical contrarian call; analyst support | | 2026-09-10 | BioCircuit Technologies acquisition (definitive agreement) | POSITIVE | Strategic catalyst; M&A announcement | | 2026-02-17 | Investor conference participation | Neutral | Routine corporate activity | | 2026-02-10 | Q4 2025 earnings date announcement | Neutral | Timing information only |

Sentiment Assessment: MIXED/TILTED NEGATIVE

  • Positive catalysts (40%): Acquisition news provides growth narrative; analyst buy-the-dip calls
  • Negative catalysts (50%): Most recent headline (Oct 16) questions valuation; competitor favoritism
  • Neutral (10%): Conference/earnings timing announcements

Catalyst Identification

Immediate Catalysts (1-7 days):

  • None identified in provided data

Near-term Catalysts (1-4 weeks):

  • Earnings Report: October 28, 2026 — Major catalyst; currently ~12 days away
    • Market expecting $10.85 move by 35 DTE, which encompasses earnings
    • Post-acquisition announcement period; results will show integration impact
    • Miss could trigger further downside; beat could spark relief rally

Medium-term Catalysts (1-3 months):

  • BioCircuit Technologies integration execution and contribution visibility
  • Analyst revisions as market digests acquisition strategic rationale

Market Narrative Alignment

Conflict Detected: Technical signals and news sentiment are DIVERGING

  • Technical narrative: Strong downtrend exhaustion (RSI 27, -63% volume) suggests capitulation
  • News narrative: Recent valuation criticism (Oct 16) and acquisition integration uncertainty suggest structural concerns
  • Resolution: Earnings on Oct 28 will be critical to reconcile these signals; if results disappoint, technical bounce could fail quickly

Risk & Volatility Assessment

Beta Interpretation: 0.82 (DEFENSIVE)

  • Below 1.0 indicates AXGN is less volatile than SPY on average
  • Typically defensive positioning, BUT current realized volatility contradicts this
  • Interpretation: Beta is historical average; current volatility regime (HV60: 51.8%) is significantly elevated above typical patterns
  • Suggests recent selloff has created unusual volatility spike not captured in beta calculation

Volatility Regime Analysis

| Metric | Value | Assessment | |--------|-------|------------| | HV 20 (Recent) | 38.8% | Elevated from baseline | | HV 30 | 51.7% | Very High | | HV 60 (3-month) | 51.8% | Sustained elevation | | IV Premium vs HV30 | +148.4% | Extreme premium | | Current IV | 128.5% | Historically high (IV Rank 100%) |

Critical Insight: Implied volatility (128.5%) is trading at **148% premium to 30-day realized volatility (

Generated
News
All AXGN news →
Earnings History
17 of 19 under expected move
Avg Expected Move
20.63%
Avg Actual Move
8.23%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2021-01-11 Pre-Market 7.68% 0.26% 0.03x Within
2022-05-04 Pre-Market 9.47% 4.29% 0.45x Within
2023-03-14 Pre-Market 7.30% 11.95% 1.64x Exceeded
2023-05-09 Pre-Market 13.04% 3.52% 0.27x Within
2023-08-07 Pre-Market 22.33% 1.66% 0.07x Within
2023-11-07 Pre-Market 64.89% 36.90% 0.57x Within
2024-01-04 Pre-Market 15.99% 1.81% 0.11x Within
2024-03-05 Pre-Market 17.47% 15.11% 0.86x Within
2024-05-02 Pre-Market 37.50% 10.37% 0.28x Within
2024-08-08 After-Close 34.58% 2.99% 0.09x Within
2024-11-07 Pre-Market 22.67% 13.44% 0.59x Within
2025-01-10 unknown 9.59% 1.15% 0.12x Within
2025-02-25 After-Close 19.27% 3.23% 0.17x Within
2025-05-08 Pre-Market 17.39% 23.18% 1.33x Exceeded
2025-08-05 Pre-Market 24.50% 9.32% 0.38x Within
2025-10-29 After-Close 15.28% 1.93% 0.13x Within
2026-02-24 Pre-Market 15.62% 8.14% 0.52x Within
2026-04-28 Pre-Market 18.72% 6.60% 0.35x Within
2026-07-29 Pre-Market 18.77% 0.53% 0.03x Within

Earnings calendar: this week’s reports with expected vs actual moves →

AXGN Options Activity & IV Rank

AXGN IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 97.7%
7-DTE IV: —
Expected Move: $8.03
7-DTE Move: $8.03
Days to Exp: 24 (2026-11-20)

Options Flow

Call Volume: 10,495
Put Volume: 116
P/C Volume: 0.011
BULLISH
Call OI: 24,714
Put OI: 811
P/C OI: 0.033
Total OI: 25,525

ATM Options Pricing

ATM Call: $4.90
ATM Put: $3.12
Call %: 13.1%
Put %: 8.3%

Chain Summary

Chain Volume: 10,845
Chain OI: 26,609
Last Updated: 10/27/2026
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Dealer Positioning
TYPICAL γ

Estimated net dealer gamma is at the 65th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
65%
vs own history
GEX tilt
+0.98
OI-weighted, today
Vanna tilt
+0.01
δ-sensitivity to IV
Charm tilt
-0.09
δ-decay vs time

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 5 ATM contracts, 22k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
as of Oct 26 · No data
30 DTE / 10d —
— pts EXTREME
as of Oct 26 · ATM 106.2% / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)61.1MediumOct 27
Straddle Price (30 DTE)$8.03Oct 27
Beta Analysis

Risk Metrics

Beta: 0.8358
Alpha: 79.22%
Correlation: 0.1929
R-Squared: 3.7%
Stock Volatility: 55.1%
Market Volatility: 12.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
Moderate volatility - stock generally follows market
Beta & Alpha Over Time
Notable investors who own AXGN
4 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Citadel Hedge fund
Ken Griffin
$62.9M
0.04%
#577 of 6285+455.3%13F
Point72 Hedge fund
Steve Cohen
$10.4M
0.02%
#754 of 1945+11.0%13F
Millennium Management Hedge fund
Izzy Englander
$1.3M
0.00%
#2808 of 3716-96.5%13F
Rockefeller Capital Management Family office
Rockefeller family
$80K
0.00%
#3107 of 4729-40.8%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

AXGN Institutional Ownership (13F)

Latest filings — 2026-09-30
Diluted shares outstanding: 50,017,366 (as of 2026-06-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

263 filers55,368,636 shares$2.50B value110.70% of float
# Filer Shares Value % of Total % of Float Period
1 BlackRock, Inc. Custodian 4,419,208 $204.12M 8.18% 8.84% 2026-06-30
2 First Light Asset Management, LLC 2,748,361 $126.95M 5.09% 5.49% 2026-06-30
3 Morgan Stanley Custodian 2,747,924 $126.93M 5.08% 5.49% 2026-06-30
4 Vanguard Capital Management LLC 2,257,948 $104.29M 4.18% 4.51% 2026-06-30
5 Vanguard Group Inc Custodian 2,869,955 $93.93M 3.76% 5.74% 2025-12-31
6 Artemis Investment Management LLP 1,780,992 $74.66M 2.99% 3.56% 2026-09-30
7 Polar Capital Holdings Plc 1,500,822 $69.32M 2.78% 3.00% 2026-06-30
8 Wellington Management Group LLP Custodian 1,391,654 $64.28M 2.58% 2.78% 2026-06-30
9 Geode Capital Management, LLC Custodian 1,375,240 $63.54M 2.55% 2.75% 2026-06-30
10 Citadel Advisors LLC Custodian 1,360,831 $62.86M 2.52% 2.72% 2026-06-30
11 Goldman Sachs Group Inc Custodian 1,261,519 $58.27M 2.33% 2.52% 2026-06-30
12 State Street Corp 1,246,821 $57.59M 2.31% 2.49% 2026-06-30
13 FMR LLC Custodian 1,222,864 $56.48M 2.26% 2.44% 2026-06-30
14 Hood River Capital Management LLC 1,067,072 $49.29M 1.97% 2.13% 2026-06-30
15 T. Rowe Price Associates, Inc. 1,018,042 $47.02M 1.88% 2.04% 2026-06-30
16 WASATCH ADVISORS LP 1,121,758 $47.02M 1.88% 2.24% 2026-09-30
17 RTW INVESTMENTS, LP 1,011,576 $46.72M 1.87% 2.02% 2026-06-30
18 NEXT CENTURY GROWTH INVESTORS LLC 872,546 $40.30M 1.61% 1.74% 2026-06-30
19 UBS Group AG Custodian 836,209 $38.62M 1.55% 1.67% 2026-06-30
20 ARMISTICE CAPITAL, LLC 775,000 $35.80M 1.43% 1.55% 2026-06-30
21 BAMCO INC /NY/ 740,210 $34.19M 1.37% 1.48% 2026-06-30
22 ArrowMark Colorado Holdings LLC 711,795 $32.88M 1.32% 1.42% 2026-06-30
23 Driehaus Capital Management LLC 707,234 $32.67M 1.31% 1.41% 2026-06-30
24 TimesSquare Capital Management, LLC 689,833 $31.86M 1.28% 1.38% 2026-06-30
25 BESSEMER GROUP INC Custodian 678,970 $31.36M 1.26% 1.36% 2026-06-30
4 filers$2.50M notional
# Filer Notional Value % of Total Period
1 Jane Street Group, LLC Custodian $1.59M 63.47% 2026-06-30
2 Citadel Advisors LLC Custodian $434.19K 17.34% 2026-06-30
3 Susquehanna International Group, LLP Custodian $388.00K 15.50% 2026-06-30
4 Simplex Trading, LLC Custodian $92.38K 3.69% 2026-06-30
1 filers$351.04K notional
# Filer Notional Value % of Total Period
1 Citadel Advisors LLC Custodian $351.04K 100.00% 2026-06-30

AXGN Insider Trading (Form 4)

Latest: 2026-09-04
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-09-04 Joseph A. Tyndall Director Sell (S) −3,500 $49.70 -$173.9K EDGAR
2026-08-12 Marc A Began EVP & General Counsel Mixed — $27.75 -$2.64M EDGAR
2026-08-12 Amy McBride Wendell Director Mixed — $31.64 -$448.3K EDGAR
2026-08-11 Kathy Johnson Weiler Director Sell (S) −14,150 $45.30 -$641.0K EDGAR
2026-06-26 Kathy Johnson Weiler Director Grant (A) +4,392 RSU — EDGAR
2026-06-26 John Johnson Director Grant (A) +4,392 RSU — EDGAR
2026-06-26 Alan M Levine Director Grant (A) +4,392 RSU — EDGAR
2026-06-26 Amy McBride Wendell Director Grant (A) +4,392 RSU — EDGAR
2026-06-26 Joseph A. Tyndall Director Grant (A) +4,392 RSU — EDGAR
2026-06-26 William P. Mr. Burke Director Grant (A) +4,392 RSU — EDGAR
2026-06-26 Paul Thomas Director Grant (A) +5,579 RSU — EDGAR
2026-06-23 John Johnson Director Exer (M) +14,150 — EDGAR
2026-06-23 Joseph A. Tyndall Director Exer (M) +14,150 — EDGAR
2026-06-23 Paul Thomas Director Exer (M) +18,867 — EDGAR
2026-06-23 William P. Mr. Burke Director Exer (M) +14,150 — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

AXGN Insider Holdings

14 insiders · @ $37.46
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Guido J Neels Director 3,457,854 $129.53M -$22.68M 20 2025-06-11
2 Erick Wayne DeVinney Chief Innovation Officer 262,781 $9.84M -$1.11M 44 2026-03-18
3 Nir Naor CFO 260,868 $9.77M $0 2 2025-01-06
4 Amy McBride Wendell Director 121,329 $4.54M -$1.69M 27 2026-08-12
5 Doris Quackenbush Sales VP 92,416 $3.46M -$168.7K 1 2026-05-08
6 Jens Kemp Chief Marketing Officer 72,451 $2.71M -$428.3K 9 2026-05-08
7 Michael D Dale Chief Executive Officer 63,537 $2.38M -$2.67M 6 2026-02-27
8 Lindsey Marie Hartley CFO 63,234 $2.37M -$942.2K 7 2026-05-08
9 Alan M Levine Director 50,893 $1.91M -$43.2K 15 2026-06-26
10 Marc A Began EVP & General Counsel 50,135 $1.88M -$3.88M 9 2026-08-12
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

AXGN Board & Officers

As of SEC filings through Sep 4, 2026

Directors 8

Officers 6

Changes in the last 10 years (49)
May 1, 2026Doris Quackenbush became Sales VP
May 12, 2025Lindsey Marie Hartley became CFO
May 8, 2025The company announced the departure of Nir Naor as CFO in an SEC filing
Mar 26, 2025Michael D Dale no longer listed as a director in SEC filings
Mar 26, 2025Michael D Dale listed as Chief Executive Officer (previously CEO and President) in SEC filings
Aug 9, 2024Michael D Dale became a director
Aug 9, 2024Michael D Dale became CEO and President
Mar 25, 2024Michael Patrick Donovan reported in an SEC filing no longer being VP Operations
Mar 5, 2024Erick Wayne DeVinney listed as Chief Innovation Officer (previously VP Peripheral Nerve Science) in SEC filings
Jan 4, 2024The company announced the departure of Karen L. Zaderej as CEO in an SEC filing
Jan 1, 2024Jens Kemp became Chief Marketing Officer
Dec 20, 2023Kathy Johnson Weiler became a director
Dec 13, 2023Peter J Mariani reported in an SEC filing no longer being EVP & Chief Financial Officer
Dec 4, 2023Nir Naor became CFO
Mar 20, 2023Marc A Began became EVP & General Counsel
Mar 20, 2023Bradley Ottinger reported in an SEC filing no longer being General Counsel and CCO
Dec 13, 2022Joseph A. Tyndall became a director
Oct 24, 2022The company announced the departure of Mark Stephen Gold from the board in an SEC filing
Jul 20, 2022Eric Sandberg reported in an SEC filing no longer being Chief Commercial Officer
Jul 11, 2022William P. Mr. Burke became a director
Not reported recently (7)
  • Gregory Gene Freitag · Last reported as a director in an SEC filing dated Jun 6, 2024
  • Karen L. Zaderej · Last reported as a director in an SEC filing dated Jun 5, 2024
  • Angelo Scopelianos · Last reported as Chief R&D Officer in an SEC filing dated Mar 25, 2024
  • Maria D. Martinez · Last reported as Chief Human Resources Officer in an SEC filing dated Oct 13, 2023
  • Isabelle Billet · Last reported as Chief Strategy and BD Officer in an SEC filing dated Dec 29, 2022
  • Lisa N Colleran · Last reported as a director in an SEC filing dated Jul 11, 2018
  • Essex Woodlands Fund IX, L.P. · Last reported as a 10% owner in an SEC filing dated Nov 21, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

AXGN Proposed Insider Sales (Form 144)

Latest: 2026-08-11
Last 30d: 0 filings  ·  Last 90d: 3 filings · $4.4M notice value · 3 unique filers · 100% under 10b5-1 plans

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Top 90-day filers: MARC BEGAN (1, $3.1M) · AMY MCBRIDE-WENDELL (1, $644K) · KATHY WEILER (1, $628K)
Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-08-11 AMY MCBRIDE-WENDELL Director 13,353 $643.9K 2026-08-11 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-08-10 MARC BEGAN Officer 67,500 $3.13M 2026-08-10 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-08-07 KATHY WEILER Director 14,150 $627.6K 2026-08-07 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-05-08 AMY MCBRIDE-WENDELL Director 1,647 $70.2K 2026-05-08 Morgan Stanley Smith Barney LLC … — EDGAR
2026-05-07 JOHN H JOHNSON Director 11,050 $478.0K 2026-05-07 Morgan Stanley Smith Barney LLC … — EDGAR
2026-05-07 DORIS QUACKENBUSH Vice President of Sales 3,878 $168.7K 2026-05-07 Morgan Stanley Smith Barney LLC … — EDGAR
2026-05-07 JENS KEMP Officer 4,000 $173.8K 2026-05-07 Morgan Stanley Smith Barney LLC … — EDGAR
2026-05-07 KATHY WEILER Director 16,344 $720.6K 2026-05-07 Morgan Stanley Smith Barney LLC … — EDGAR
2025-12-16 Amy McBride-Wendell Director 43,684 $1.28M 2025-12-16 Morgan Stanley Smith Barney LLC … — EDGAR
2025-12-16 KATHY WEILER Director 46,653 $1.38M 2025-12-16 Morgan Stanley Smith Barney LLC … — EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
66 ETFs hold AXGN
25 shown · $273.57M total exposure · 0.05% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $72.1M — 2026-09-30
2 IWM iShares Russell 2000 ETF iShares (BlackRock) 0.07% $51.0M $74.6B 2026-10-23
3 VXF Vanguard Extended Market ETF Vanguard 0.03% $27.8M — 2026-09-30
4 IWO iShares Russell 2000 Growth ETF iShares (BlackRock) 0.14% $18.8M $13.7B 2026-10-23
5 VTWO Vanguard Russell 2000 ETF Vanguard 0.07% $13.0M — 2026-09-30
6 FESM Fidelity Enhanced Small Cap Core ETF Fidelity 0.18% $11.8M $6.6B 2026-10-23
7 IHI iShares U.S. Medical Devices ETF iShares (BlackRock) 0.29% $10.5M $3.6B 2026-10-23
8 DFAS Dimensional US Small Cap ETF Dimensional 0.03% $10.0M — 2026-10-23
9 SCHA Schwab U.S. Small-Cap ETF Nport 0.04% $9.5M — 2026-05-31
10 VHT Vanguard Health Care ETF Vanguard 0.03% $6.5M — 2026-09-30
11 DFMC Dimensional US Micro Cap ETF Dimensional 0.07% $5.1M — 2026-10-23
12 PTH Invesco Dorsey Wright Healthcare Momentum ETF Nport 2.06% $4.8M — 2026-07-31
13 FYC First Trust Small Cap Growth AlphaDEX® Fund First Trust 0.35% $4.6M $1.3B 2026-10-23
14 USVM VictoryShares US Small Mid Cap Value Momentum ETF Nport 0.25% $4.4M — 2026-06-30
15 PSC Principal U.S. Small-Cap ETF Nport 0.17% $3.9M — 2026-06-30
16 ITOT iShares Core S&P Total U.S. Stock Market ETF iShares (BlackRock) 0.00% $2.8M $96.5B 2026-10-23
17 FSMD Fidelity Small-Mid Multifactor ETF Fidelity 0.10% $2.5M $2.5B 2026-10-23
18 VFMO Vanguard U.S. Momentum Factor ETF Vanguard 0.13% $2.5M — 2026-10-23
19 VTWG Vanguard Russell 2000 Growth ETF Vanguard 0.15% $2.4M — 2026-09-30
20 NUSC Nuveen ESG Small-Cap ETF Nport 0.16% $2.0M — 2026-07-31
21 XHE State Street® SPDR® S&P® Health Care Equipment ETF SPDR (State Street) 1.25% $1.9M $151.1M 2026-10-23
22 DWAS Invesco Dorsey Wright SmallCap Momentum ETF Nport 0.41% $1.7M — 2026-05-31
23 FYX First Trust Small Cap Core AlphaDEX® Fund First Trust 0.11% $1.5M $1.4B 2026-10-23
24 SCHB Schwab U.S. Broad Market ETF Nport 0.00% $1.3M — 2026-05-31
25 HTEC ROBO Global Healthcare Technology and Innovation ETF Nport 1.77% $1.2M — 2026-07-31
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-0.68
TTM Revenue
$251.17M
TTM Net Income
$-33.55M
TTM Op. Cash Flow
$15.05M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q2 '262026-06-30$69.73M$-1.52M$-0.03$7.22M
Q1 '262026-03-31$61.46M$-19.58M$-0.38$1.56M
Q4 '252025-12-31$59.90M$-13.16M$-0.28$3.04M
Q3 '252025-09-30$60.08M$708.00K$0.01$3.22M
Q2 '252025-06-30$56.66M$579.00K$0.01$7.73M
Q1 '252025-03-31$48.56M$-3.83M$-0.08$-13.18M
Q4 '242024-12-31$49.41M$450.00K$0.01$8.73M
Q3 '242024-09-30$48.64M$-1.86M$-0.04$3.90M
Q2 '242024-06-30$47.91M$-1.92M$-0.04$4.17M
Q1 '242024-03-31$41.38M$-6.63M$-0.15$-12.27M
Q4 '232023-12-31$42.92M$-3.89M$-0.09$-211.00K
Q3 '232023-09-30$41.27M$-4.09M$-0.10$1.63M
Q2 2026 • period ending 2026-06-30 • filed 2026-07-29
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
7.31
P/S
7.46
EV/EBITDA
—
EV/Sales
7.08
ROE
-13.1%
ROA
-11.0%
Div Yield
0.00%
FCF Yield
0.80%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$1.87B
as of 2026-10-27
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
4.70M
SI % of Float
9.31%
Days to Cover
4.17
Short Vol Ratio
45.8%
Free Float
50.44M
Float %
93.8%
Short interest 2026-09-30 • Short volume 2026-10-27 • Float 2026-08-24